Canada Gene Therapy Market Size & Outlook, 2023-2030
- Biotechnology
- Gene Expression & Gene Therapy
- Gene Therapy Market Outlook
- Gene Expression & Gene Therapy
Canada Gene Therapy Market, 2018-2030 (US$M)
Global Market
Related Markets
Ask a question about the gene therapy market
Canada gene therapy market highlights
- The Canada gene therapy market generated a revenue of USD 119.0 million in 2023 and is expected to reach USD 194.0 million by 2030.
- The Canada market is expected to grow at a CAGR of 7.2% from 2024 to 2030.
- In terms of segment, other vector type was the largest revenue generating vector type in 2023.
- Lentivirus is the most lucrative vector type segment registering the fastest growth during the forecast period.
Gene therapy market data book summary
| Market revenue in 2023 | USD 119.0 million |
| Market revenue in 2030 | USD 194.0 million |
| Growth rate | 7.2% (CAGR from 2024 to 2030) |
| Largest segment | Other vector type |
| Fastest growing segment | Lentivirus |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Lentivirus, RetroVirus & gamma RetroVirus, Other Vector Type |
| Key market players worldwide | Regenxbio Inc, Oxford Biomedical Research, Bristol-Myers Squibb Co, Sanofi SA, Ultragenyx Pharmaceutical Inc, Roche Holding AG ADR, Bluebird bio Inc, Novartis AG ADR, UniQure NV, Cellectis SA, Sangamo Therapeutics Inc, Benitec Biopharma Inc, SiBiono GeneTech, Transgene SA, Gensight Biologics SA, Astellas Pharma Inc |
Other key industry trends
- In terms of revenue, Canada accounted for 1.4% of the global gene therapy market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. gene therapy market is projected to lead the regional market in terms of revenue in 2030.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 18,484.0 million by 2030.
Health Canada has approved numerous gene therapies since 2016. In September 2016, Novartis announced approval for Kymriah by Health Canada. This was the first Chimeric Antigen Receptor T-cell (CAR-T) therapy to secure regulatory approval in this country.
Similarly, in February 2019, Gilead Sciences secured approval from Health Canada for Yescarta. These significant approvals depict the country’s growth in the gene therapy market.
Moreover, an increasing number of clinical studies related to gene therapies are expected to create growth opportunities in the market in the coming years. As of April 2022, 323 gene therapies were in clinical trials.
Key Regions:U.S., UK, Japan, South Korea, China
No credit card required*
Publish Date: Mar 17, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Gene Therapy Market Scope
Gene Therapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Novartis AG ADR | View profile | 76,057 | Lichtstrasse 35, Basel, Switzerland, 4056 | www.novartis.com |
| Roche Holding AG ADR | View profile | 103,605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | www.roche.com |
| Sanofi SA | View profile | 87,994 | 46, avenue de la Grande Armée, Paris, France, 75017 | www.sanofi.com |
| Bristol-Myers Squibb Co | View profile | 34,100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | www.bms.com |
| UniQure NV | View profile | 480 | Paasheuvelweg 25, Amsterdam, NH, Netherlands, 1105 BP | www.uniqure.com |
| SiBiono GeneTech | View profile | 1001-5000 | Shenzhen, Guangdong, China, Asia | www.sibiono.com |
| Cellectis SA | View profile | 216 | 8, rue de la Croix Jarry, Paris, France, 75013 | www.cellectis.com |
| Astellas Pharma Inc | View profile | 14,484 | 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan, 103-8411 | www.astellas.com |
| Bluebird bio Inc | View profile | 323 | 455 Grand Union Boulevard, Somerville, MA, United States, 02145 | www.bluebirdbio.com |
| Sangamo Therapeutics Inc | View profile | 405 | 501 Canal Boulevard, Richmond, CA, United States, 94804 | www.sangamo.com |
Canada Gene Therapy Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Gene Therapy Market Outlook will help companies and investors design strategic landscapes.
Other Vector Type was the largest segment with a revenue share of 53.95% in 2023.
Horizon Databook has segmented the Canada gene therapy market based on lentivirus, retrovirus & gamma retrovirus, other vector type covering the revenue growth of each sub-segment from 2018 to 2030.
Health Canada has approved numerous gene therapies since 2016. In September 2016, Novartis announced approval for Kymriah by Health Canada. This was the first Chimeric Antigen Receptor T-cell (CAR-T) therapy to secure regulatory approval in this country.
Similarly, in February 2019, Gilead Sciences secured approval from Health Canada for Yescarta. These significant approvals depict the country’s growth in the gene therapy market.
Moreover, an increasing number of clinical studies related to gene therapies are expected to create growth opportunities in the market in the coming years. As of April 2022, 323 gene therapies were in clinical trials.
- Canada Gene Therapy Market Vector Type Outlook (Revenue, USD Million , 2018-2030)
- Lentivirus
- AAV
- RetroVirus & gamma RetroVirus
- Modified Herpes Simplex Virus
- Adenovirus
- Non-viral Plasmid Vector
- Other Vector Type
- Canada Gene Therapy Market Indication Outlook (Revenue, USD Million , 2018-2030)
- Acute Lymphoblastic Leukemia (ALL)
- Inherited Retinal Disease
- Large B-cell Lymphoma
- ADA-SCID
- Melanoma (lesions)
- Beta-Thalassemia Major/SCD
- Head & Neck Squamous Cell Carcinoma
- Peripheral arterial disease
- Spinal Muscular Atrophy (SMA)
- Others
Reasons to subscribe to Gene Therapy Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Gene Therapy Market Outlook databook
- Our clientele includes a mix of Gene Therapy Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada Gene Therapy Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Canada Gene Therapy Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Canada Gene Therapy Market, 2018-2030 (US$M)
Canada gene therapy market statistics, by vector type, 2018-2030 (US$M)
